BioMarin Pharmaceutical (BM8) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BM8 Analyst Ratings

Strong Buy

13 Buy

4 Hold

0 Sell

Based on 17 analysts giving stock ratings to

BioMarin

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BM8 Stock 12 Month Forecast

Average Price Target

€77.85

▲(52.18% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is €77.85 with a high forecast of €104.81 and a low forecast of €48.04. The average price target represents a 52.18% change from the last price of €51.16.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"€43","74":"€74","105":"€105","58.5":"€58.5","89.5":"€89.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":104.8140204,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€104.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77.85352515266666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€77.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.039759350000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€48.04</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,58.5,74,89.5,105],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.48,54.65954003076923,58.83908006153846,63.018620092307685,67.19816012307692,71.37770015384615,75.55724018461538,79.73678021538461,83.91632024615384,88.09586027692308,92.27540030769231,96.45494033846154,100.63448036923077,{"y":104.8140204,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.48,52.585655780974356,54.691311561948716,56.796967342923075,58.902623123897435,61.008278904871794,63.11393468584615,65.2195904668205,67.32524624779487,69.43090202876922,71.53655780974358,73.64221359071794,75.7478693716923,{"y":77.85352515266666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.48,50.29228918076923,50.10457836153846,49.91686754230769,49.72915672307692,49.54144590384615,49.35373508461539,49.166024265384614,48.97831344615385,48.79060262692308,48.60289180769231,48.41518098846154,48.22747016923077,{"y":48.039759350000004,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":66.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.22,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.54,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.42,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.94,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.71,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.48,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€104.81

Average Price Target€77.85

Lowest Price Target€48.04

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mohit Bansal

Wells Fargo

€65.51

Buy

28.05%

Upside

Reiterated

03/16/26

Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weaknessWells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness

Yun Zhong

Wedbush

€82.1

Buy

60.49%

Upside

Assigned

03/16/26

Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside

Jason Gerberry

Bank of America Securities

€84.72→€74.24

Buy

45.12%

Upside

Reiterated

03/11/26

BioMarin: Strategic Amicus Acquisition Supports Buy Rating Despite Voxzogo Assumption Reset

Joon Lee

Truist Financial

―

Buy

―

Reiterated

03/03/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Eliana Merle

Barclays

€69.88→€91.71

Buy

79.27%

Upside

Assigned

03/03/26

BioMarin price target raised to $105 from $80 at BarclaysBioMarin price target raised to $105 from $80 at Barclays

Mitchell Kapoor

H.C. Wainwright

€48.04

Hold

-6.10%

Downside

Reiterated

03/02/26

H.C. Wainwright Remains a Hold on BioMarin Pharmaceutical (BMRN)

Olivia Brayer

Cantor Fitzgerald

€74.24

Buy

45.12%

Upside

Reiterated

03/02/26

Cantor Fitzgerald Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Whitney Ijem

Canaccord Genuity

€85.6→€90.84

Buy

77.56%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (NASDAQ: IMCR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Schrodinger (NASDAQ: SDGR)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

€92.59→€75.12

Buy

46.83%

Upside

Reiterated

02/24/26

Guggenheim Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

Cory Kasimov

Evercore ISI

€96.08

Buy

87.80%

Upside

Reiterated

02/24/26

Evercore ISI Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Sami Corwin

William Blair

―

Hold

―

Reiterated

02/24/26

Balanced Risk-Reward Amid Evolving Growth Profile and Rising Competition at BioMarin

Phil Nadeau

TD Cowen

€104.81

Buy

104.87%

Upside

Reiterated

02/24/26

BioMarin: Strong Q4 Beat, Solid Multi‑Year Outlook, and Strategic Amicus Acquisition Support Buy Rating

William Pickering

Bernstein

€78.61→€82.1

Buy

60.49%

Upside

Assigned

02/24/26

BioMarin price target raised to $94 from $90 at BernsteinBioMarin price target raised to $94 from $90 at Bernstein

Luca Issi

RBC Capital

€57.65

Hold

12.68%

Upside

Reiterated

02/23/26

Analysts Are Neutral on These Healthcare Stocks: Pliant Therapeutics (PLRX), Summit Therapeutics (SMMT)

Akash Tewari

Jefferies

€98.7

Buy

92.92%

Upside

Reiterated

02/12/26

BioMarin Pharmaceutical (BMRN) Gets a Buy from Jefferies

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mohit Bansal

Wells Fargo

€65.51

Buy

28.05%

Upside

Reiterated

03/16/26

Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weaknessWells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness

Yun Zhong

Wedbush

€82.1

Buy

60.49%

Upside

Assigned

03/16/26

Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside

Jason Gerberry

Bank of America Securities

€84.72→€74.24

Buy

45.12%

Upside

Reiterated

03/11/26

BioMarin: Strategic Amicus Acquisition Supports Buy Rating Despite Voxzogo Assumption Reset

Joon Lee

Truist Financial

―

Buy

―

Reiterated

03/03/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Eliana Merle

Barclays

€69.88→€91.71

Buy

79.27%

Upside

Assigned

03/03/26

BioMarin price target raised to $105 from $80 at BarclaysBioMarin price target raised to $105 from $80 at Barclays

Mitchell Kapoor

H.C. Wainwright

€48.04

Hold

-6.10%

Downside

Reiterated

03/02/26

H.C. Wainwright Remains a Hold on BioMarin Pharmaceutical (BMRN)

Olivia Brayer

Cantor Fitzgerald

€74.24

Buy

45.12%

Upside

Reiterated

03/02/26

Cantor Fitzgerald Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Whitney Ijem

Canaccord Genuity

€85.6→€90.84

Buy

77.56%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (NASDAQ: IMCR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Schrodinger (NASDAQ: SDGR)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

€92.59→€75.12

Buy

46.83%

Upside

Reiterated

02/24/26

Guggenheim Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

Cory Kasimov

Evercore ISI

€96.08

Buy

87.80%

Upside

Reiterated

02/24/26

Evercore ISI Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Sami Corwin

William Blair

―

Hold

―

Reiterated

02/24/26

Balanced Risk-Reward Amid Evolving Growth Profile and Rising Competition at BioMarin

Phil Nadeau

TD Cowen

€104.81

Buy

104.87%

Upside

Reiterated

02/24/26

BioMarin: Strong Q4 Beat, Solid Multi‑Year Outlook, and Strategic Amicus Acquisition Support Buy Rating

William Pickering

Bernstein

€78.61→€82.1

Buy

60.49%

Upside

Assigned

02/24/26

BioMarin price target raised to $94 from $90 at BernsteinBioMarin price target raised to $94 from $90 at Bernstein

Luca Issi

RBC Capital

€57.65

Hold

12.68%

Upside

Reiterated

02/23/26

Analysts Are Neutral on These Healthcare Stocks: Pliant Therapeutics (PLRX), Summit Therapeutics (SMMT)

Akash Tewari

Jefferies

€98.7

Buy

92.92%

Upside

Reiterated

02/12/26

BioMarin Pharmaceutical (BMRN) Gets a Buy from Jefferies

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

3 Months

xxx

Success Rate

15/36 ratings generated profit

Average Return

-0.46%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of -0.46% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

21/43 ratings generated profit

Average Return

-3.06%

a rating ―

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 48.84% of your transactions generating a profit, with an average return of -3.06% per trade.

2 Years

xxx

Success Rate

11/26 ratings generated profit

Average Return

-6.17%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 42.31% of your transactions generating a profit, with an average return of -6.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BM8 Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BM8 has received 27 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. BM8 average Analyst price target in the past 3 months is 77.85.

Each month's total comprises the sum of three months' worth of ratings.

BM8 Financial Forecast

BM8 Earnings Forecast

Next quarter’s earnings estimate for BM8 is €0.64 with a range of €0.45 to €1.04. The previous quarter’s EPS was -€0.21. BM8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BM8 has Performed in-line its overall industry.

BM8 Sales Forecast

Next quarter’s sales forecast for BM8 is €660.89M with a range of €611.42M to €690.99M. The previous quarter’s sales results were €781.75M. BM8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BM8 has Performed in-line its overall industry.

BM8 Stock Forecast FAQ

What is DE:BM8’s average 12-month price target, according to analysts?

Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 77.85.

What is DE:BM8’s upside potential, based on the analysts’ average price target?

BioMarin Pharmaceutical has 52.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BioMarin Pharmaceutical a Buy, Sell or Hold?

BioMarin Pharmaceutical has a consensus rating of Strong Buy, which is based on 13 buy ratings, 4 hold ratings and 0 sell ratings.

What is BioMarin Pharmaceutical’s share price target?

The average share price target for BioMarin Pharmaceutical is 77.85. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €104.81 ,and the lowest forecast is €48.04. The average share price target represents 52.18% Increase from the current price of €51.16.

What do analysts say about BioMarin Pharmaceutical?

BioMarin Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of BioMarin Pharmaceutical?

To buy shares of DE:BM8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

BioMarin Pharmaceutical (BM8) Stock Forecast & Price Target

BM8 Analyst Ratings

BM8 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioMarin Pharmaceutical

BM8 Analyst Recommendation Trends

BM8 Financial Forecast

BM8 Earnings Forecast

BM8 Sales Forecast

BM8 Stock Forecast FAQ

Detailed List of Analyst Forecasts